Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.60 |
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.51 |
| ▸ | IKBKB | O14920 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380076 | 0.85 | JAK2 (0.68) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL4380256 | 0.83 | JAK2 (0.65) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL4378143 | 0.80 | JAK2 (0.90) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL13588599 | 0.76 | JAK2 (0.81) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL4383820 | 0.76 | JAK2 (1.00) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL8084292 | 0.75 | JAK2 (0.67) | JAK2JAK3HDAC6HDAC1PLK1 | |
| SCHEMBL4388808 | 0.75 | JAK2 (0.79) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL4376505 | 0.75 | JAK2 (0.79) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL7470447 | 0.74 | JAK2 (0.79) | JAK2JAK3HDAC6HDAC1IKBKB | |
| SCHEMBL4390308 | 0.74 | JAK2 (1.00) | JAK2JAK3HDAC6HDAC1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | JAK2 150/4885JAK3 218/4885HDAC6 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.